NEWS

Apr 07

I-SPY 2 TRIAL GRADUATES NERATINIB FOR HER2-POSITIVE BREAST CANCER

The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer, according to research presented at the 2014 AACR Annual Meeting. According to the trial, which used an algorithm to identify which patients would receive the most benefit from a variety of different treatments, neratinib had an estimated pathological complete response (pCR) of 55% for patients in the trial with HR-negative, HER2-positive breast cancer. Based on these findings, further evaluation in the phase III I-SPY 3 study is planned.